On August 3, the Senate approved, 94-1, H.R. 2430, the Food and Drug Administration (FDA) Reauthorization Act. The House approved its version of the legislation, sponsored by Rep. Greg Walden (R-OR), on July 12 (see The Source, 7/14/17).
The bill would authorize the FDA to collect user fees for prescription drugs, medical devices, generic drugs, and biosimilar products.
